Enbioco인바이오
352940 · KOSDAQ · ₩352940 · 인바이오
Valuation model · Discounted cash flow (DCF)
We use a 5-year discounted cash flow: the value of the cash the business is expected to produce, in today's money.
Fair value per share
With these assumptions the model gives no positive value.
- Enterprise value
- −₩24B
- Equity value
- −₩46B
- WACC
- 5.7%
Model estimate based on the assumptions shown. Not a price target and not a buy or sell signal. This is not financial advice.
Why the model and the price differ
The model gives no positive value at these assumptions. What we can see:
- To match today's price of ₩1,884, the model needs an operating margin of 9.2% every year (it uses −0.1%).
- Margins ranged from −14.0% to 3.9% over the last 5 years, so this is a cyclical business. The model uses the average; the price may be set by where the cycle is now. Try the margin fade option.
- In the projection, spending on equipment, software and working capital takes most or all of the after-tax operating profit, so free cash flow is thin. Companies that invest heavily often look like this until spending slows.
Treat the model as a starting point: change the assumptions to the story you believe, and compare with the multiples check below.
Bear / Base / Bull
- Bear
- —
- Base
- —
- Bull
- —
Bear: revenue growth 3 points lower every year, EBIT margin 2 points lower, WACC 1 point higher. Bull: the opposite.
Assumptions
Sign in to change the assumptions and see the results update. Sign in
Cycle options
Margin path
Every year uses the cycle-average margin (−0.1%).
Revenue growth
- -0.3%
How much sales grow that year, compared with the year before.
Default: the last 3 years' revenue growth (-0.3% a year, annual reports), fading to 3% by year 5.
- 0.5%
How much sales grow that year, compared with the year before.
Default: the last 3 years' revenue growth (-0.3% a year, annual reports), fading to 3% by year 5.
- 1.4%
How much sales grow that year, compared with the year before.
Default: the last 3 years' revenue growth (-0.3% a year, annual reports), fading to 3% by year 5.
- 2.2%
How much sales grow that year, compared with the year before.
Default: the last 3 years' revenue growth (-0.3% a year, annual reports), fading to 3% by year 5.
- 3%
How much sales grow that year, compared with the year before.
Default: the last 3 years' revenue growth (-0.3% a year, annual reports), fading to 3% by year 5.
Business
- -0.1%
Operating profit as a share of revenue.
Default: through-the-cycle average of the last 12 months and the last 5 annual reports' operating margins.
- 27.5%
Share of operating profit paid as corporate tax.
Default: Korea's top corporate tax rate (25%) plus 10% local income tax.
- 13%
The non-cash cost of wearing out equipment, added back to cash flow (% of revenue).
Default: not in the statements, so 80% of capital spending (most spending replaces equipment that wears out).
- 16.2%
Money spent on factories, equipment, software and other long-term assets (% of revenue).
Default: average of the last 3 annual reports (cash flow statements; equipment and intangibles).
- 40%
Stock and unpaid customer bills, less unpaid supplier bills, as a % of revenue. Each year's extra revenue ties up this much more cash.
Default: working capital (current assets less cash and deposits, minus current liabilities other than borrowings) as a share of revenue, averaged over the last 3 years.
Discount rate
- 2%
How fast cash flows keep growing every year after year 5.
Default: about Korea's long-run inflation plus real growth.
- 4.08%
Yield on Korea's 10-year government bond: the return with almost no risk.
Default: Korea Treasury Bond 10-year yield on 2026-10-29.
- 0.6
How much the share moves when the market moves: 1 means just like the market.
Default: 105 weeks of weekly returns against KOSPI (official index); raw beta 0.19, adjusted toward 1 and kept between 0.6 and 2.0.
- 5.5%
The extra return investors want for owning shares instead of bonds.
Default: a typical premium for Korean shares.
- 5.58%
The interest rate the company would pay to borrow.
Default: the 10-year yield plus a 1.5% credit spread.
Starting point
- Revenue (TTM to H1 2026)
- ₩36B
- Net debt (borrowings and leases − cash and deposits)
- ₩22B
- Shares
- 10,867,730
- Share price
- ₩1,884
- Market cap
- ₩20B
TTM = trailing 12 months: the last four reported quarters added together. "TTM to H1 2026" is the 12 months up to the latest quarterly or half-year report (H1 = to the end of June). Year 1 grows from there.
Past years and projection
Grey columns are reported results from the annual reports (after-tax EBIT at the model's tax rate), so you can check the growth and margin assumptions against the past. Years 1–5 are the model.
| FY2023 | FY2024 | FY2025 | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₩34B | ₩36B | ₩34B | ₩36B | ₩36B | ₩37B | ₩38B | ₩39B |
| Growth | −0.6% | 4.8% | −4.8% | −0.3% | 0.5% | 1.4% | 2.2% | 3.0% |
| EBIT | −₩3.4B | ₩1.4B | ₩917M | −₩36M | −₩36M | −₩37M | −₩38M | −₩39M |
| EBIT margin | −9.9% | 3.9% | 2.7% | −0.1% | −0.1% | −0.1% | −0.1% | −0.1% |
| After-tax EBIT | −₩2.4B | ₩1B | ₩665M | −₩26M | −₩26M | −₩27M | −₩27M | −₩28M |
| + Depreciation | — | — | — | ₩4.7B | ₩4.7B | ₩4.8B | ₩4.9B | ₩5B |
| − Capital spending | ₩1.1B | ₩8.8B | ₩7.1B | ₩5.8B | ₩5.9B | ₩6B | ₩6.1B | ₩6.3B |
| − Working capital | −₩7.2B | −₩3.3B | −₩7.3B | −₩43M | ₩72M | ₩203M | ₩324M | ₩451M |
| Free cash flow | — | — | — | −₩1.1B | −₩1.3B | −₩1.4B | −₩1.6B | −₩1.7B |
| Discount factor | — | — | — | 0.946 | 0.896 | 0.848 | 0.802 | 0.760 |
| Present value | — | — | — | −₩1.1B | −₩1.1B | −₩1.2B | −₩1.2B | −₩1.3B |
Terminal value −₩23B, worth −₩18B today: 75% of enterprise value. It assumes spending settles at 110% of depreciation once growth slows to the terminal rate.
Cross-check: what the market has paid before
For cyclical businesses, analysts check a DCF against the multiples the stock has traded at through past cycles. Price / book is the usual anchor for them: P/E looks highest at the bottom of a cycle, when earnings are smallest, and lowest at the top. The price each band would give today:
| Low | Typical | High | |
|---|---|---|---|
| Price / book (book value ₩4,097 a share)Now 0.46× | ₩2,1630.53× | ₩3,0020.73× | ₩5,7091.39× |
Low, typical and high are the 10th percentile, middle and 90th percentile of month-end multiples since 2021, each against the latest report out by then, per share at today's share count; loss years and P/E above 100 are left out. Run-rate earnings are one quarter × 4, not a forecast. Model estimate based on the assumptions shown. Not a price target and not a buy or sell signal.
Sensitivity
Fair value per share as two inputs change; the middle is the current case.
| WACC ↓ · Terminal growth → | 1.0% | 1.5% | 2.0% | 2.5% | 3.0% |
|---|---|---|---|---|---|
| 4.7% | — | — | — | — | — |
| 5.2% | — | — | — | — | — |
| 5.7% | — | — | — | — | — |
| 6.2% | — | — | — | — | — |
| 6.7% | — | — | — | — | — |
Now (TTM)
- Market cap
- ₩20B
- Enterprise value
- ₩42B
- P/E
- 35.6×
- P/B
- 0.5×
- P/S
- 0.6×
- EV/EBITDA
- —
- Dividend yield
- 0.0%
Over time (at each year end)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Price | ₩2,275 | ₩2,020 | ₩3,505 | ₩4,265 | ₩7,950 |
| Market cap | ₩25B | ₩22B | ₩38B | ₩46B | ₩86B |
| P/E | 24.5× | 34.0× | — | — | 16.5× |
| P/B | 0.6× | 0.5× | 0.9× | 1.0× | 1.7× |
| P/S | 0.7× | 0.6× | 1.1× | 1.4× | 2.6× |
| EV/EBITDA | — | — | — | — | — |
| Dividend yield | 0.0% | — | — | — | — |
Versus similar companies
| Company | P/E | P/B | P/S | EV/EBITDA | Dividend yield |
|---|---|---|---|---|---|
| Enbioco | 35.6× | 0.5× | 0.6× | — | 0.0% |
| LG Chem | — | 0.5× | 0.3× | — | 0.9% |
| Hanwha Solutions | — | 0.5× | 0.3× | — | 0.0% |
| Hanwha | 6.1× | 0.4× | 0.1× | — | 1.4% |
| SKC | — | 1.8× | 1.7× | — | 0.0% |
| KCC | 0.9× | 0.3× | 0.5× | 9.0× | 0.0% |
| Kumho Petro Chemical | 5.2× | 0.4× | 0.4× | — | 1.6% |
| Similar companies (median) | 5.2× | 0.4× | 0.4× | 9.0× | 0.4% |
Calculated from end-of-day prices and filed financial statements. Not a recommendation. This is not financial advice.
Also known as: Enbioco / 인바이오 / 352940 / KRX:352940
Source: KRX statistical information